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Abstract
Background: Three percent of the world's population is chronically infected with hepatitis C virus
(HCV) and thus at risk of developing liver cancer. Although precise mechanisms regulating HCV
entry into hepatic cells are still unknown, several cell surface proteins have been identified as entry
factors for this virus. Among these molecules, the tetraspanin CD81 is essential for HCV entry.
Interestingly, CD81 is also required for Plasmodium infection. A major characteristic of tetraspanins
is their ability to interact with each other and other transmembrane proteins to build tetraspanin-
enriched microdomains (TEM).
Results: In our study, we describe a human hepatoma Huh-7 cell clone (Huh-7w7) which has lost
CD81 expression and can be infected by HCV when human CD81 (hCD81) or mouse CD81
(mCD81) is ectopically expressed. We took advantage of these permissive cells expressing mCD81
and the previously described MT81/MT81w mAbs to analyze the role of TEM-associated CD81 in
HCV infection. Importantly, MT81w antibody, which only recognizes TEM-associated mCD81, did
not strongly affect HCV infection. Furthermore, cholesterol depletion, which inhibits HCV
infection and reduces total cell surface expression of CD81, did not affect TEM-associated CD81
levels. In addition, sphingomyelinase treatment, which also reduces HCV infection and cell surface
expression of total CD81, raised TEM-associated CD81 levels.
Conclusion: In contrast to Plasmodium infection, our data show that association of CD81 with
TEM is not essential for the early steps of HCV life cycle, indicating that these two pathogens, while
using the same molecules, invade their host by different mechanisms.
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Approximately 130 million people are infected world-
wide by Hepatitis C Virus (HCV) [1]. Almost 80% of
infected patients develop a chronic hepatitis that can in
the long term evolve either to liver cirrhosis or hepatocel-
lular carcinoma. Unfortunately, no vaccine is currently
available to prevent new infections and the current treat-
ments are not fully efficient [2]. HCV is an enveloped RNA
virus mainly targeting liver cells by a mechanism that has
yet to be elucidated. For a long time, it has been difficult
to study the different steps of the HCV life cycle because
of the difficulties in propagating this virus in cell culture.
However, a major step in investigating HCV entry was
achieved in the development of pseudotyped particles
(HCVpp), consisting of native HCV envelope glycopro-
teins, E1 and E2, assembled onto retroviral core particles
[3-5]. More recently, the development of a cell culture sys-
tem allowing an efficient amplification of HCV (HCVcc)
has also been reported [6-8]. This cell culture system
allows the study of the whole life cycle of HCV and,
together with HCVpp, also permits the characterization of
HCV entry mechanisms.
Although the early steps of viral entry have yet to be eluci-
dated, accumulated data suggest several cell surface-
expressed molecules as entry factors for HCV (reviewed in
[9]). Among these molecules, the tetraspanin CD81 has
been shown to play a key role in HCV entry, acting during
a post-attachment step [10,11]. Like all members of the
tetraspanin family, CD81 is composed of four transmem-
brane domains, a small extracellular loop (SEL) and a
large extracellular loop (LEL), which contains a conserved
CCG amino acid motif involved in the formation of
disulfide bridges [12]. The CD81 LEL is the critical region
for the interaction with the E2 envelope glycoprotein and
for virus entry. The role of CD81 in the species restriction
of HCV has been extensively studied [13-18], and it has
been recently shown that in spite of the absence of in vitro
interaction between murine CD81 (mCD81) LEL and a
soluble form of HCV E2, the ectopic expression of
mCD81 in HepG2 cells restored permissivity to HCVpp
and, in a lesser extent, to HCVcc [15]. These results suggest
that CD81 contributes to, but alone does not define, the
species restriction and additional cellular factors are likely
involved. Moreover, we have recently shown that EWI-
2wint, a new partner of CD81, is able to modulate HCV
entry in target cells suggesting that, in addition to the pres-
ence of specific entry factors in the hepatocytes, the
absence of a specific inhibitor may contribute to the hepa-
totropism of HCV [19].
Members of the tetraspanin family organize and regroup
their associated transmembrane proteins and are involved
in various functions such as cell morphology, motility,
fusion and signalling [12,20]. A major characteristic of tet-
raspanins is their ability to interact with each other and
with other transmembrane proteins, thus building multi-
molecular membrane complexes, collectively referred to
as the tetraspanin enriched microdomains (TEM) or tet-
raspanin webs [21,22]. Membrane cholesterol contributes
to the organization of these domains on the surface of live
cells [23]. Cholesterol is also critical to many pathogens,
including HCV [24] and Plasmodium infection [23]. Inter-
estingly, it has been shown that CD81 is required for Plas-
modium sporozoite entry and differentiation into
hepatocytes [25,26]. Using a monoclonal antibody
(mAb) that specifically recognizes a subset of mouse
CD81 molecules associated with TEMs (MT81w), Silvie et
al. have defined the role of TEM-associated CD81 in mice
Plasmodium infection [23]. The similarities between Plas-
modium and HCV liver infections indicate the importance
of studying the role of TEM-associated CD81 in HCV
infection.
In our study, infection of Huh-7 target cells with highly
infectious HCVcc particles allowed us to isolate a cellular
clone resistant to HCV infection which has lost CD81
expression (Huh-7w7 cells). We then took advantage of
the emergence of these CD81-deficient cells to analyze the
functionality of mCD81 in HCV infection and to study the
role of TEM-associated CD81 in HCV infection.
Results
Generation of Huh-7 cells resistant to HCV infection
In a previous study, we have shown that a HCV JFH-1 full-
length RNA genome encoding mutations in the capsid
and E2 sequences (JFH-1/CS-N6) releases highly infec-
tious HCVcc particles which display a marked cytopathic
effect on target cells [27]. Infection of Huh-7 cells with
these particles led to the selection of few living cells that
were resistant to HCV infection. In order to analyze the
capacity of these cells to resist to HCVcc infection, they
were amplified and treated with interferon α to eliminate
any potential remaining virus. This cell population, called
Resistant 1 (R1), displayed reduced levels of JFH-1 HCVcc
infection compared to parental Huh-7 cells (Figure 1A).
In parallel, we infected the R1 cell population with retro-
viral particles harboring HCV envelope glycoproteins of
genotypes 1a or 2a (HCVpp-1a or HCVpp-2a, respec-
tively) and found reduced levels of HCVpp infection in
comparison to Huh-7 cells (Figure 1B). Both cell lines
were not infected by particles devoid of envelope proteins
(data not shown) and were equally infected with the pos-
itive control VSVpp, which infects virtually all type of cells
(Figure 1B).
To further analyze this cellular resistance to HCV infec-
tion, cellular clones were isolated by limiting dilution and
their sensitivity to HCVcc and HCVpp infection was ana-
lyzed. As shown in Figure 1C, several clones were resistantPage 2 of 18
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exhibited some susceptibility to HCVcc (clones 1, 2, 4, 5,
6 and 16), but greatly reduced when compared to the
parental Huh-7 cells. Interestingly, analysis of the sensitiv-
ity of several clones to HCVpp infection showed similar
reduced infectivity levels (Figure 1D), indicating that the
entry step of HCV life cycle is affected in these cells. The
only major difference was observed for clone 6, which was
barely permissive for JFH-1 infection but highly permis-
sive for HCVpp, suggesting that replication or assembly of
HCVcc is likely affected in these cells.
Ectopic expression of human and mouse CD81 in resistant 
cells restores HCV permissivity
The HCV entry stage is a multistep process involving sev-
eral cellular factors (reviewed in [9]). Among these mole-
cules, the tetraspanin CD81, the Scavenger Receptor class
B type I (SR-BI), and the tight junction protein claudin 1
(CLDN-1) play key roles. Since the absence of one of these
molecules might explain the differences in infectivity of
the R1 cell clones, their expression levels were examined
(Figure 1E). Experiments of surface biotinylation fol-
lowed by immunoprecipitations with specific mAbs
showed that the cell surface expression levels of SR-BI and
CLDN-1 were similar in each clone, whereas CD81 expres-
sion differed among the clones. CD81 cellular expression
levels in R1 cell clones were also tested by anti-CD81 west-
ern-blotting over total cell lysates and similar results were
obtained (data not shown). Interestingly, non permissive
R1 cell clones were also negative for CD81 expression,
indicating that HCV entry defect observed in clones 3, 7,
8, 10, 12 and 14 is likely due to the absence of CD81
expression.
To confirm our hypothesis, we ectopically expressed
CD81 in one of the non-permissive Huh-7 R1 cell clones
(clone 7) that we called Huh-7w7 cells. Plasmids express-
ing human CD81 (hCD81), mouse CD81 (mCD81) or
empty expression vector (pcDNA3.1) were stably trans-
fected in Huh-7w7 cells. The CD81 expression level was
next controlled by flow cytometry analysis using 1.3.3.22
anti-hCD81 (Figure 1F, left panel) and MT81 anti-
mCD81 (Figure 1F, right panel) mAbs. Cell surface
expression of hCD81 in Huh-7w7/hCD81 cells was
higher than in parental Huh-7 cells, whereas no hCD81
expression was detectable in Huh-7w7/pcDNA3.1 and
Huh-7w7/mCD81 cells. mCD81 was also highly
expressed in Huh-7w7/mCD81 cells (Figure 1F, right
panel) and expression level was comparable with the one
of Hepa1.6 cells that naturally express mouse CD81 (data
not shown). Huh-7 cells and the complemented Huh-
7w7 populations displayed similar expression levels of
the control tetraspanin CD151 (data not shown).
We next tested the sensitivity of the different cell lines to
HCVcc and HCVpp infection. Control cells expressing the
empty vector pcDNA3.1 were totally resistant to HCV
infection (Figures 1G and 1H). In contrast, Huh-7w7/
hCD81 cells were equally or slightly more infected by
HCVpp than parental Huh-7 cells (Figure 1H). Thus,
ectopic expression of hCD81 fully restores permissivity to
HCVpp harboring HCV envelope glycoproteins from dif-
ferent genotypes indicating that CD81 expression is likely
the only defect for HCV entry in Huh-7w7 cells. However,
the level of infectivity of Huh-7w7/hCD81 cells by HCVcc
was 50%, as compared to the one of Huh-7 cells, indicat-
ing that despite being highly expressed, hCD81 did not
fully restore permissivity to HCVcc. Overexpression of
CD81 (Figure 1F) in Huh-7w7/hCD81 cells may lead
CD81 to oligomerize, as shown for CD9 another tet-
raspanin [28], in less permissive CD81 molecules to
HCVcc infection. The entry efficiency of HCVpp will not
be affected in this context but only driven by CD81
Ectopic expression of CD81 in HCV-resistant Huh-7 cells restores HCV permissivityFigure 1 (se  previous page)
Ectopic expression of CD81 in HCV-resistant Huh-7 cells restores HCV permissivity. A, Huh-7 cells and R1 cell 
population infected with JFH-1 HCVcc were processed for double-label immunofluorescence for capsid protein (green) and 
nuclei (blue, Hoechst). B, Cells were infected with virus pseudotyped with HCV envelope proteins from 1a (HCVpp 1a) or 2a 
(HCVpp 2a) or VSV G envelope protein (VSVpp). C, Huh-7 cells and R1 individual cellular clones were infected with HCVcc 
expressing Renilla luciferase. In parallel, Huh-7 cells and some of the clones were infected with HCVpp 1a, HCVpp 2a or VSVpp 
(D). Results are presented as relative percentages to HCVcc (C) and HCVpp (D) infectivity on Huh-7 cells. HCVpp infections 
(D) were also normalized to VSVpp infections on Huh-7 cells. E, Surface biotinylated cell lysates were immunoprecipitated 
with anti-CD81 (5A6), anti-SR-BI (NB400-104H3) or anti-CLDN-1 (JAY.8) mAbs. Proteins were revealed by Western blotting 
with HRP-conjugated streptavidin. F, Flow cytometry analysis of CD81 cell surface expression. Cells were stained using an 
anti-hCD81 (1.3.3.22, left panel) or an anti-mCD81 (MT81, right panel), and secondary antibodies conjugated with PE. Ctrl 
corresponds to Huh-7 cells stained only with secondary antibodies. Cell lines were infected with HCVcc (G) and in parallel 
with HCVpp (H) generated with envelope proteins from different genotypes or virus pseudotyped with feline endogenous 
virus RD114 glycoprotein (Rd114pp). Results are presented as relative percentages to HCVcc (G) and HCVpp (H) infectivity 
on Huh-7 cells. P < 0.05 as calculated by the Mann-Whitney's test; *, statistically not significant difference in HCVpp entry com-
pared to entry into Huh-7 cells.Page 4 of 18
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HCVcc and HCVpp entries have already been shown [29].
Interestingly, ectopic expression of mCD81 in Huh-7w7
cells was also able to restore HCV permissivity. As shown
in Figure 1G, the level of permissivity to HCVcc of Huh-
7w7/mCD81 cells was 20% of the one of parental Huh-7
cells. In addition, permissivity of Huh-7w7/mCD81 cells
to HCVpp bearing glycoproteins from different genotypes
was analyzed and showed that mCD81 supports infection
with HCVpp from genotypes 2a and 4, with 29% and 19%
of level of infectivity respectively, as compared to the one
of Huh-7 cells (Figure 1H). In contrast to Flint et al. [15],
we did not observe any significant infectivity for HCVpp
harboring glycoproteins from genotypes 1a and 1b.
It is worth noting that the sensitivity of Huh-7w7/mCD81
cells to HCV infection is solely due to the expression of
mCD81 since anti-hCD81 mAbs (1.3.3.22; Figure 2 and
5A6; not shown) efficiently inhibited HCVcc and HCVpp
infection of Huh-7 and Huh-7w7/hCD81 cells, but did
not significantly affect the infectivity of Huh-7w7/mCD81
cells. These results indicate that no residual expression of
hCD81 is responsible for permissivity since in such a case
infection would be fully inhibited by the anti-hCD81
mAbs. Control experiment performed with irrelevant
antibodies did not inhibit HCV infectivity (data not
shown).
Taken together, these data indicate that HCV infection is
directly related to CD81 expression in Huh-7w7 cells.
Most importantly, mCD81 in the context of such human
hepatocytes is able to some extent to mimic the role of
hCD81 in HCV entry and likely interacts in a similar way
with cellular factors.
Role of TEM-associated CD81 in HCV entry
Tetraspanins associate extensively with each other and
other membrane proteins to form the TEMs. Recently, Sil-
vie et al. have described the MT81w mAb, which specifi-
cally recognizes mouse CD81 associated with other
tetraspanins. This is evidenced by the lack of recognition
of CD81 after cell lysis with detergents that do not pre-
serve tetraspanin-tetraspanin interactions, and by the
complete removal of the CD81 pool recognized by
MT81w following immunodepletion of tetraspanin com-
plexes [23]. CD81 is required for invasion of hepatocytes
by sporozoites of human malaria Plasmodium falciparum
and rodent malaria Plasmodium yoelii parasites [26]. Using
MT81w antibody, Silvie et al. have shown that the subset
of CD81 associated with TEMs contributes to Plasmodium
sporozoite infection [23]. Such an antibody preferentially
recognizing human CD81 associated with TEMs is not
available. However, since Huh-7w7/mCD81 cells are sus-
ceptible to HCVcc and HCVpp-2a infection, we next took
Anti-hCD81 mAb inhibits HCV infection of hCD81 express-ing cells but not of Huh-7w7/mCD81 cellsFi ure 2
Anti-hCD81 mAb inhibits HCV infection of hCD81 
expressing cells but not of Huh-7w7/mCD81 cells. 
HCVcc (upper panel) and HCVpp 2a (lower panel) infections 
of cell lines were performed in absence (white histograms) 
or presence (black histograms) of 1.3.3.22 anti-hCD81 mAb 
(3 μg/ml). At 2 days post-infection, cells were lysed and proc-
essed as described in methods. P < 0.05 as calculated by the 
Mann-Whitney's test; *, statistically not significant difference 
in HCVcc infectivity compared to infectivity in absence of 
antibodies.Page 5 of 18
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role of TEM-associated CD81 in the early steps of HCV life
cycle.
Using the MT81w anti-mCD81 mAb, we first character-
ized the subpopulation of mCD81 that is associated with
TEMs on the cell surface of Huh-7w7/mCD81 cells (Figure
3A). As shown by flow cytometry analysis, the intensity of
MT81w labeling only reached 32 ± 14%, depending on
the experiment, of the intensity with MT81 in Huh-7w7/
mCD81 cells, indicating that only a fraction of CD81 mol-
ecules is engaged in tetraspanin microdomains on these
cells, as described for Hepa1–6 cells [23]. However, we
cannot exclude that the lower affinity of MT81w may lead
to an underestimate of the ratio of CD81 engaged in
TEMs. The specificity of MT81w to recognize TEM-associ-
ated CD81 in Huh-7w7/mCD81 cells was confirmed by
immunoprecipitation experiments from biotinylated cell
lysates made under different detergent conditions. Tet-
raspanin microdomains are typically disrupted by Triton
X-100, but are retained in less hydrophobic detergents
such as Brij 97 [30]. As shown in Figure 3B, 5A6 and MT81
mAbs precipitated hCD81 and mCD81, respectively,
under both detergent condition. In contrast, MT81w was
able to precipitate mCD81 only from Brij97 lysates pre-
serving tetraspanin-tetraspanin interactions, but not from
Triton X-100 lysates. These results show that expression of
mCD81 in Huh-7w7 cells allowed to reconstitute tet-
raspanin webs that are specifically recognized by the well
characterized MT81w mAb [23].
To ensure that similar molecular web interactions occur in
Huh-7w7/mCD81 and Huh-7 cells, we next analyzed
TEM composition in immunoprecipitation experiments
of surface biotinylated cell lysates. Since lysis in Brij 97
preserves tetraspanin-tetraspanin interactions, any anti-
tetraspanin mAb can co-immunoprecipitate the entire set
of proteins present in tetraspanin microdomains [31]. The
tetraspanin pattern obtained with Huh-7 cells using 5A6
hCD81 mAb is shown in Figure 3C. The major proteins
co-immunoprecipitated with CD81 have an apparent
molecular mass consistent with that of EWI-2 and EWI-F,
two major partners of CD81 [30,32,33]. The identity of
these proteins was confirmed by direct immunoprecipita-
tion (Figure 3C and data not shown), as previously
described [19]. Interestingly, MT81 and MT81w immuno-
precipitations of mCD81 in Huh-7w7/mCD81 cells gave
a pattern similar to that of hCD81 in Huh-7 cells (Figure
3C). EWI-2 and EWI-F proteins were co-immunoprecipi-
tated with mCD81 in Huh-7w7/mCD81 cells. In addi-
tion, immunoprecipitation with an anti-CD151, another
tetraspanin, co-immunoprecipitated a fraction of mCD81
in Huh-7w7/mCD81 cells as well as hCD81 in Huh-7
cells (Figure 3C, lines TS151). Altogether, in spite of slight
differences in stoichiometry, these results show that
mCD81 in Huh-7w7/mCD81 cells is engaged in similar
web interactions than hCD81 in Huh-7 cells.
We then analyzed the ability of MT81 and MT81w to
inhibit HCVcc and HCVpp infectivity. As shown in Figures
4A and 4B, MT81 mAb, which recognizes the whole pop-
ulation of CD81, efficiently inhibited both HCVcc infec-
tion and HCVpp entry into Huh-7w7/mCD81 cells.
Indeed, MT81 inhibited 80% of HCVcc infection and 95%
of HCVpp infection at low concentrations (3 μg/ml). In
contrast, MT81w was poorly neutralizing since it only
induced an inhibition of 40% and 60% of HCVcc and
HCVpp infection, respectively, at tenfold higher concen-
trations (30 μg/ml). However, it has to be noted that
MT81w mAb might be a low-affinity antibody, as com-
pared to MT81 [23]. The specificity of the observed inhib-
itory effect was ensured by using an irrelevant antibody at
the highest concentration (anti-transferrin receptor anti-
body CD71 at 30 μg/ml, Figure 4 TR30). As expected,
MT81 and MT81w did not affect HCVcc or HCVpp infec-
tivity levels of Huh-7 cells (data not shown).
Together, our results suggest that TEM-associated CD81
molecules might not play a central role in HCV entry.
However, since we cannot exclude a partial recognition of
TEM-associated CD81 molecules by the low affinity
MT81w mAb or that the epitope recognized by this anti-
body is located outside of the E2 binding region, we fur-
ther analyzed the role of TEM-associated CD81 in HCV
entry using other approaches.
Role of cholesterol in HCV infection and the association of 
CD81 with TEM
Cellular cholesterol has been shown to modulate the
organization of tetraspanin microdomains [23] and to be
involved in HCV life cycle [34]. To further analyze the role
of TEM-associated CD81 in HCV infection, we next
assessed the effect of cholesterol depletion on HCV infec-
tion. Huh-7w7/mCD81 cells were treated with increasing
amounts of methyl-beta-cyclodextrin (MβCD), a cyclic
oligosaccharide that selectively removes cholesterol from
the plasma membrane without incorporating into the
membrane [35]. Treatment of Huh-7w7/mCD81 cells
with MβCD prior to infection resulted in a dose-depend-
ent inhibition of HCVcc (Figure 5A) and HCVpp-2a (Fig-
ure 5B) infectivity. In both set of experiments the maximal
inhibition of HCV infection was reached at an MβCD con-
centration of 15 mM, which decreased the cellular choles-
terol content by fivefold (data not shown). Moreover,
inhibition of infection was specifically due to cholesterol
removal from the cell surface, since it was reversed by cho-
lesterol replenishment with MβCD-cholesterol complexes
before HCV infection (Figures 5C and 5D). Such pre-
formed MβCD-cholesterol complexes are known to
replenish cells with cholesterol [36]. It has to be notedPage 6 of 18
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Recognition of TEM-associated CD81 in Huh-7w7/mCD81 cellsFigure 3
Recognition of TEM-associated CD81 in Huh-7w7/mCD81 cells. A, Flow cytometry analysis of Huh-7w7/mCD81 cells 
stained with the mAbs MT81 and MT81w. Cells stained only with PE-conjugated secondary antibody were used as control 
(dotted line). B, Cell lines were surface biotinylated and lysed in the presence of Brij97 or Triton X-100 before immunoprecip-
itation with MT81, MT81w and 5A6 mAbs. Immunoprecipitates were revealed by western blotting using peroxidase-conju-
gated streptavidin. C, Cell lines were surface biotinylated and lysed in buffer containing 1% Brij97 and divalent ions. 
Immunoprecipitations were then performed with 5A6, MT81, MT81w, 8A12 (anti-EWI-2), TS151 (anti-CD151) or irrelevant 
(CTL) mAbs. Immunoprecipitates were revealed by western blotting using peroxidase-conjugated streptavidin. The molecular 
weights of the prestained molecular ladders are indicated in KDa. The asterisks indicate dimers of CD81.
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Neutralization assay of HCV infection with MT81 and MT81w antibodiesFig e 4
Neutralization assay of HCV infection with MT81 and MT81w antibodies. HCVcc (A) and HCVpp 2a (B) infections 
of Huh-7w7/mCD81 cells were performed in presence of indicated concentrations of MT81 (left panels) or MT81w (right pan-
els) mAbs or in presence of 30 μg/ml of transferrin receptor (right panels, TR30). At 2 days post-infection, cells were lysed and 
processed as described in methods. P < 0.05 as calculated by the Mann-Whitney's test.
BMC Microbiology 2009, 9:111 http://www.biomedcentral.com/1471-2180/9/111
Page 9 of 18
(page number not for citation purposes)
Depletion of cellular cholesterol decreases HCV infection of Huh-7w7/mCD81 cellsFigure 5
Depletion of cellular cholesterol decreases HCV infection of Huh-7w7/mCD81 cells. Huh-7w7/mCD81 cells were 
pretreated with increasing concentrations of MβCD prior to infection with HCVcc (A) or HCVpp 2a (B). Huh-7w7/mCD81 
cells were untreated (NT) or pretreated with 7.5 mM of MβCD (MβCD) and then treated or not with 2.5 mM of preformed 
MβCD-Cholesterol complexes (Chol) (C and D). After treatment, cells were infected with HCVcc (C) or HCVpp-2a or VSVpp 
(D). At 2 days post-infection, cells were lysed and processed as described in methods. P < 0.05 as calculated by the Mann-
Whitney's test; *, statistically not significant difference in HCV infectivity compared to infectivity in absence of drugs.
BMC Microbiology 2009, 9:111 http://www.biomedcentral.com/1471-2180/9/111that MβCD treatment had no effect on VSVpp entry (Fig-
ure 5D), which is clathrin dependent, indicating that
HCVpp entry inhibition was not due to disruption of
clathrin-enriched domains following cholesterol deple-
tion [37-39]. In addition, cell treatment with MβCD at 15
mM three hours after cell/virus contact did not have any
effect on infection (data not shown), indicating that
membrane cholesterol is required at the entry step and
MβCD is not toxic under our experimental conditions.
Cholesterol depletion and replenishment experiments
were performed on Huh-7 cells and gave similar results
(data not shown).
Altogether, our data confirm the role of cholesterol in
HCV entry and bring to light a similar response of Huh-
7w7/mCD81 and Huh-7 cells to cholesterol depletion
and replenishment in terms of HCV infection.
We next analyzed by flow cytometry the surface expres-
sion of CD81 and its association with TEMs in Huh-7w7/
mCD81 cells treated with MβCD or MβCD-cholesterol
complexes (Figure 6), and expression of CD151 was used
as a control (right panels). MβCD treatment of Huh-7w7/
mCD81 cells reduced MT81 labelling by 58 ± 7% (Figure
6Aa), suggesting that cholesterol depletion induced a
decrease in total cell surface expression of mCD81 in
Huh-7w7/mCD81 cells. Even with cholesterol replenish-
ment, CD81 expression level could not be restored to con-
ditions that would enable HCV infectivity (Figure 6Ac,
MβCD+Chol). Incubation of MβCD-treated cells with
increasing concentrations of preformed MβCD-choles-
terol complexes raised cell surface mCD81 expression
level (Figure 6B). However, a concentration four times
higher than needed to reverse the inhibitory effect of
MβCD on HCV infectivity (10 mM instead of 2,5 mM)
was necessary to reach the cell surface mCD81 expression
level of untreated cells. Interestingly, treatment with
MβCD alone had no effect on TEM-associated mCD81
population in Huh-7w7/mCD81 cells, as determined
using MT81w (Figure 6Ab). Conversely, cholesterol
enrichment of non depleted cells with preformed MβCD-
cholesterol complexes led to a 2 ± 0.6 fold increase of
TEM-associated mCD81 population (Figure 6Af), without
any change in the total CD81 population (Figure 6Ae).
These results confirm the role of cholesterol in TEM
organization. Expression of CD151 under different condi-
tions was not affected (Figure 6A, right panels).
Our results differ from those of Silvie et al. showing that
similar MβCD treatment of Hepa1–6 cells did not lead to
a significant decrease of total CD81 cell surface expression
[23]. However, it has to be noted that the tetraspanin
CD9, expressed in Hepa1–6 cells but not in Huh-7 cells,
has been shown to increase stability of tetraspanin com-
plexes [40].
In conclusion, cellular cholesterol depletion mediated by
MβCD strongly affects HCV infection, but it has no effect
on TEM-associated mCD81 in Huh-7w7/mCD81 cells.
Again, these data do not support a key role for TEM-asso-
ciated CD81 molecules in HCV infection.
Finally, we ensured that MβCD-induced inhibition of
HCV entry did not lead to a reduced expression level of
another HCV entry factor. We analyzed the expression lev-
els of SR-BI, CLDN-1 and LDL receptor (LDL-R), three
other major actors of HCV entry [9]. The tetraspanin
CD151 was used again as a control. Since no antibody
against extracellular loops of CLDN-1 is available for flow
cytometry, we performed our analyses by immunoprecip-
itation of surface biotinylated cell lysates. As shown
above, treatment of Huh-7w7/mCD81 cells with MβCD
was accompanied by a reduced expression level of CD81,
as detected by MT81 (Figure 7). We also found a reduced
immunoprecipitation of CD81 by MT81w after MβCD
treatment. Cholesterol depletion prior to lysis in Brij 97
likely led to a harsher effect of the detergent leading to a
partial dissociation of tetraspanin complexes recognized
by MT81w. Interestingly, treatment of Huh-7w7/mCD81
cells with MβCD did not lead to a reduction of cell surface
expression of SR-BI, CLDN-1 or LDL-R. It has to be noted
that SR-BI and CLDN-1 seemed even more expressed after
MβCD treatment (Figure 7). This increased expression of
SR-BI after MβCD treatment was confirmed by flow
cytometry (data not shown) and has been previously
described by others [24,41-43]. It has also been suggested
that CLDN-1 might be in membrane domains resistant to
MβCD treatment [44,45]. Altogether, our results show
that MβCD-induced inhibition of HCV entry was solely
due to reduced levels of cholesterol and CD81.
Role of ceramide in TEM-associated CD81 and in HCV 
infection
Beyond cholesterol, sphingolipids are also known to be
important for the organization of the plasma membrane.
Among them, sphingomyelin can be converted into cera-
mide by sphingomyelinase (Smase), and increasing cera-
mide concentration can lead to lipid microdomain
reorganization [46]. We have previously reported that
ceramide enrichment of the plasma membrane of Huh-7
cells following sphingomyelin hydrolysis by sphingomy-
elinase strongly inhibits HCV entry and reduces CD81 cell
surface expression level by 50% [47]. Since sphingomye-
lin influences CD81 cell surface expression as well as HCV
infection, we sought to determine the effect of the Smase
treatment on TEM-associated CD81 population. Huh-
7w7/mCD81 cells were pre-treated with Smase, washed
and then infected with HCVcc or HCVpp-2a. Similarly to
Huh-7 cells, Huh-7w7/mCD81 cells were affected by
Smase treatment, resulting in 70–80% and 50–60% inhi-Page 10 of 18
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Cholesterol depletion affects total CD81 cell surface expressionFigure 6
Cholesterol depletion affects total CD81 cell surface expression. A, Flow cytometry analysis of CD81 and CD151 
expression on the cell surface of Huh-7w7/mCD81 cells. Upper panels: cells were treated with 7.5 mM of MβCD (MβCD) or 
left untreated (NT). Middle panels: cells were treated with 7.5 mM of MβCD (MβCD) followed by 2.5 mM of MβCD-Choles-
terol (MβCD + Chol). Lower panels: cells were treated with 2.5 mM of MβCD-Cholesterol (Chol) or left untreated (NT). B, 
Cells were treated with 7.5 mM of MβCD (MβCD) followed by increasing concentrations (in mM) of MβCD-Cholesterol 
(MβCD + Chol) and total cell surface CD81 expression compared to untreated cells (NT) was measured using MT81 mAb.
BMC Microbiology 2009, 9:111 http://www.biomedcentral.com/1471-2180/9/111bition of HCVcc and HCVpp-2a infection, respectively
(Figure 8A).
In order to determine whether these inhibitions were
associated with changes in cell surface expression of
CD81, we analyzed by flow cytometry the CD81 surface
expression level after Smase treatment (Figure 8B). Inter-
estingly, Smase treatment of Huh-7w7/mCD81 cells led
to a significant reduction (52 ± 18%) in MT81 labelling
and conversely to significant increase (277 ± 74%) in
MT81w labelling, indicating that the treatment induced a
reduction of total mCD81 expression and an increased
association of CD81 with TEM. As expected, Smase treat-
ment did not affect the expression of the control tet-
raspanin CD151 (Figure 8B).
We next ensured that Smase-induced inhibition of HCV
entry was not also associated with reduced expression
level of another HCV entry factor. As described above, we
analyzed the expression levels of SR-BI, CLDN-1 and LDL-
R after treatment of Huh-7w7/mCD81 cells with Smase.
As shown above (Figure 8B), treatment with Smase was
accompanied by a reduced expression level of CD81, as
detected by MT81 (Figure 7). In accordance with our pre-
vious results (Figure 8B), we also found an increased
immunoprecipitation of CD81 by MT81w after Smase
treatment. Interestingly, expression level of SR-BI, CLDN-
1 or LDL-R were not affected following treatment of cells
with Smase (Figure 7).
Thus, Smase treatment of Huh-7w7/mCD81 cells resulted
in HCV entry inhibition and increase of TEM-associated
mCD81 population. In agreement with previous data,
these results indicate that TEM-associated CD81 does not
play a major role in HCV entry. Smase treatment resulted
also in a significant decrease of cell surface expression of
CD81 on Huh-7 cells (data not shown), as described pre-
viously [47]. The similarity of Huh-7 and Huh-7w7/
mCD81 cells responses to Smase treatment tends to show
that results obtained with Huh-7w7/mCD81 cells can be
extrapolated to Huh-7 cells.
Discussion and conclusion
We have previously shown that mutations (CS-N6) in the
structural proteins of the JFH-1 genome increase the pro-
duction and infectivity of HCVcc particles, leading to an
accelerated cytopathic effect [27]. Interestingly, infection
of Huh-7 cells with such particles led us to isolate cellular
clones exhibiting different levels of permissivity to HCVcc
and HCVpp. For most of them, reduced HCV infection
levels were directly related to their reduced expression
level of CD81, while other entry molecules such as SR-BI
and CLDN-1 were not modified. Our observation is in
accordance with previously published data [29,48-50].
Ectopic expression of CD81 in Huh-7w7 cells, one of the
resistant cell clones, restored HCV permissivity indicating
that CD81 deficiency alone was responsible for the resist-
ance to HCV infection in these cells. In agreement with
previous studies [29,48,51], we did not observe any varia-
tion in HCV genome replication in Huh-7w7 cells in com-
parison to Huh-7 cells (data not shown), suggesting that
CD81 is not involved in this step of the viral cycle. Mas-
ciopinto et al. showed that CD81 and HCV envelope glyc-
oproteins could be detected in exosomes of mammalian
cells, suggesting that HCV may intracellularly interact
with CD81 allowing its export [52]. They pointed out a
possible role of CD81 in assembly and release of HCV
particles. However, our results indicate that CD81 does
not participate to HCV assembly or release of new viral
particles, since the supernatant of Huh-7w7 cells trans-
fected with full-length HCV RNA infected naïve Huh-7
Cholesterol depletion and ceramide enrichment do not reduce cell surface expression of oth r HCV entry factorsFig r  7
Cholesterol depletion and ceramide enrichment do 
not reduce cell surface expression of other HCV 
entry factors. Huh-7w7/mCD81 cells were treated with 7.5 
mM MβCD, with 0.5 unit Smase/ml or left untreated (NT) 30 
min at 37°C. Cells were then surface biotinylated and lysed 
in buffer containing 1% Brij97 and divalent ions. Immunopre-
cipitations were performed with indicated mAbs. Immuno-
precipitates were revealed by western blotting using 
peroxidase-conjugated streptavidin.Page 12 of 18
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transfected Huh-7 cells. Thus, Huh-7w7 cells constitute a
new tool allowing to investigate the involvement of CD81
in HCV entry and offering a new single-cycle replication
system, as already used by others [29].
The molecular determinants of HCV-CD81 interaction
have been analyzed by several groups by using biochemi-
cal assays (reviewed in [53]). However, Flint et al have
highlighted the limitation of these approaches since vari-
ous mutated CD81 sequences previously reported to abro-
gate E2-CD81 interaction, were able to restore
permissivity in HepG2 cells [15]. In our study, we show
that ectopic expression of human and mouse CD81 pro-
teins in human hepatoma cells devoid of CD81 conferred
susceptibility to infection by HCVcc and HCVpp at vari-
ous levels. Interestingly, mCD81 protein supports infec-
tion by HCVcc and HCVpp bearing glycoproteins from
genotypes 2a and 4 suggesting that, in accordance with
other studies [15,17], CD81 is not the sole determinant of
species susceptibility to HCV. Other additional cellular
factors likely modulate HCV entry. In addition, interac-
Ceramide enrichment of the plasma membrane of Huh-7w7/mCD81 cells inhibits HCV entry and increases association of D81 with TEMsFigure 8
Ceramide enrichment of the plasma membrane of Huh-7w7/mCD81 cells inhibits HCV entry and increases 
association of CD81 with TEMs. A, Huh-7w7/mCD81 cells were pretreated (+Smase) or not (-Smase) with Smase prior to 
infection with HCVcc or HCVpp 2a. At 2 days post-infection, cells were lysed and processed as described in methods. P < 0.05 
as calculated by the Mann-Whitney's test. B, Huh-7w7/mCD81 cells pretreated (+Smase) or not (-Smase) with Smase were 
stained with MT81 (left panel), MT81w (middle panel) or TS151 (right panel) mAbs. Cells stained only with PE-conjugated sec-
ondary antibody were used as control (dotted line).Page 13 of 18
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factors and plasma membrane lipids may regulate species
susceptibility to HCV.
CD81 belongs to the tetraspanin family of which mem-
bers have the distinctive feature of clustering dynamically
with numerous partner proteins and with one another in
membrane microdomains. Within this web, the associa-
tions of tetraspanins with their nontetraspanin partner
molecules have been referred to as primary, and tet-
raspanin can interact with each other through their asso-
ciated partner [12]. In contrast to primary complexes,
tetraspanin-tetraspanin interactions are not stoichiomet-
ric and palmitoylation is necessary for the maintenance of
these interactions [28,40,54,55]. It is still unknown
whether all tetraspanins expressed in a certain cell are
associated with each other. Importantly, tetraspanins
associate indirectly with additional proteins. Function-
ally, these interactions cluster in TEM, enabling lateral
dynamic organization in the membrane and the cross-talk
with intracellular signalling and cytoskeletal structures
[21]. In our study, generation of a human cell line express-
ing mCD81 (Huh-7w7/mCD81 cells) permissive to HCV
infection allowed us to analyze the role of TEM-associated
CD81 in HCV infection. This study could be performed
with two recently described mAbs: MT81, which recog-
nizes total mCD81; and MT81w, which specifically recog-
nizes a fraction of mCD81 associated with other
tetraspanins [23]. It is worth noting that such a tool allow-
ing the detection of hCD81 associated with TEMs is not
available. We first determined the inhibitory effect of both
mAbs on HCVcc and HCVpp infection: MT81 strongly
inhibited HCV infection, whereas MT81w led to a weak
inhibition of infection at saturing concentrations. This
reduced capacity of MT81w mAb to inhibit HCV infection
suggests that TEM-associated CD81 molecules, recognized
by this mAb, are not the exclusive site of infection. In
accordance with these results, ceramide enrichment of
plasma membrane leading to an increased association of
CD81 with TEMs highly inhibits HCV infection. While
palmitoylation is not the only mechanism by which tet-
raspanins interact with each other, it has been shown to
play an essential role in TEM organization [28,40,54,55].
The ability of palmitoylation-defective CD81 to support
infection by HCVpp [10] is again consistent with a minor
role of TEM-associated CD81 in HCV entry. We cannot
exclude that the epitope recognized by MT81w mAb on
CD81 is not involved in HCV interaction. The partial inhi-
bition of MT81w might also be the reflect of a partial rec-
ognition of the TEM-associated CD81 fraction, as
previously suggested by Silvie et al. [23].
The entire HCV life cycle is associated with cholesterol
metabolism in host cells (reviewed in [34]), and lipid
composition of the plasma membrane seems very impor-
tant for the HCV entry step. In our study, we showed that
cholesterol depletion by treatment with MβCD strongly
reduced HCV entry into target cells, and conversely cho-
lesterol replenishment by MβCD-cholesterol complexes
restored the infection levels. These results point out again
the importance of cell membrane cholesterol in HCV
entry, likely in the fusion process as has been previously
suggested [56]. Very recently, we have shown that increas-
ing the levels of ceramide in the plasma membrane induce
a massive endocytosis of CD81 leading to a strong inhibi-
tion of HCV infection [47]. Interestingly, in the present
study, we showed that following Smase treatment of Huh-
7w7/mCD81 cells, expression of CD81 is inversely related
to association of CD81 with tetraspanin webs. These
results suggest that ceramide might specifically modify the
levels of interaction or the cell surface distribution of
TEM. In this regard, it has been shown that gangliosides
play an important role in the organization of CD82-
enriched microdomains [57]. Ceramide enrichment may
also induce clustering of CD81 leading to an increased
binding of MT81w mAb. In accordance with this hypoth-
esis, it has been shown that high levels of ceramide induce
large-scale clustering/capping of death receptors (e.g. Fas/
CD95) required to initiate efficient formation of death-
induced signalling complex [58,59]. Alternatively,
MT81w may recognize an epitope of CD81 that is more
exposed following ceramide enrichment. Further analyses
are necessary to evaluate these hypotheses.
HCV and Plasmodium are two major pathogens targeting
the liver. Both use the glycosaminoglycans for their initial
attachment on the surface of hepatocytes [11,60-64], and
lipidic transfer properties of scavenger receptor class B
type I regulate infection of both pathogens [9,65,66].
CD81 is required for HCV and Plasmodium life cycle. Anti-
bodies to CD81 or CD81 silencing strongly reduce the
infection of hepatic cells and CD81-deficient mouse hepa-
tocytes are resistant to infection by Plasmodium [26].
Using CD81/CD9 chimeras, it has been recently shown
that CD81 LEL plays a critical role in sporozoite infection
and a stretch of 21 amino acids is sufficient to confer sus-
ceptibility to infection [66]. In contrast to HCV infection,
it seems that CD81 does not act directly as a receptor but
is rather involved indirectly, likely by modulating the
activity of an associated protein. This hypothesis is sup-
ported by the fact that CD81 associated to multiple pro-
teins in the tetraspanin web plays a major role in
sporozoite infection, since modulation of cellular choles-
terol levels, which changes tetraspanin microdomain
organization, has been shown to also modify the extent of
CD81-dependent sporozoite infection [23]. In contrast, in
our study, we demonstrated that TEM-associated CD81 is
not used by HCV, indicating that these two pathogens,
while using the same molecules, invade their host by dif-
ferent mechanisms.Page 14 of 18
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Antibodies
5A6 (anti-CD81 kindly provided by S. Levy); ACAP27
(anti-HCV core, kindly provided by JF Delagneau); MT81
(anti-CD81), MT81w (anti-TEM associated CD81), 8A12
(anti-EWI-2) and TS151 (anti-CD151) mAbs were used in
this study. The anti-Claudin-1 (JAY.8) was from Zymed,
the anti-SR-BI (NB400-104H3) was from Novus, the anti-
LDL receptor was from Progen, the anti-transferrin recep-
tor antibody was from Biolegend (Ozyme) and the anti-
hCD81 (1.3.3.22) was from Santa Cruz Biotechnology.
Alexa488-conjugated goat anti-mouse was from Jackson
Immunoresearch.
Production of HCVcc and infection assays
Production of HCVcc and infection assays were performed
as described [19]. To generate HCVcc expressing Renilla
luciferase, we used the FL-J6/JFH-5'C19Rluc2AUbi
genome [67] kindly provided by C.M. Rice (The Rockfeller
University, New York). We replaced the region encoding
the J6/JFH-1 HCV polyprotein with the CS-N6 JFH-1
sequence [27]. HCVcc were produced as previously
described [7,27,67]. HCVcc were added to Huh-7 cells
seeded the day before and incubated for 2 h at 37°C. The
supernatants were then removed and the cells were incu-
bated in DMEM 10% FBS at 37°C. At 40–48 h post-infec-
tion, cells were lysed and processed to measure the Renilla
luciferase activities as indicated by the manufacturer
(Promega). Luciferase activities were normalized for pro-
tein concentration in each cell lysate. In each figure,
results are reported as the mean ± S.D. of three independ-
ent experiments.
Generation of R1 cell population and resistant cellular 
clones
Huh-7 cells were infected (m.o.i. = 1) with JFH-1/I2/CS-
N6 particles [27] 4 h at 37°C and then maintained for sev-
eral weeks. Survival cells were amplified and treated with
200 UI/ml of IFN α. After six successive treatments with
IFN α, cells were analysed by immunofluorescence and
western blotting and subcloned by limiting dilution. The
cells were seeded in 96-well plates at 1 cell/well in DMEM
10% FCS. Individual cell clones were amplified and
named Huh-7w with a number corresponding to the
clone.
Cell transfection
Huh-7w7 cells were transfected using ExGen500 (Euro-
gentec) with plasmids expressing human CD81
(pcDNA3.1/hCD81), murine CD81 (pcDNA3.1/mCD81)
[30] or the empty vector. Polyclonal populations were
obtained by selection for 4 weeks with 600 μg/ml of Neo-
mycin (Invitrogen).
Antibody neutralization assay
Neutralization assays were performed by co-incubating
HCVcc/HCVpp and antibodies with target cells 3 h at
37°C. Cells were further incubated for 48 h with DMEM
10% FCS before measuring the luciferase activities.
Cholesterol depletion/replenishment and 
sphingomyelinase (Smase) treatment
Cholesterol depletion was carried out by incubating cells
with different concentrations of methyl-β-cyclodextrin
(MβCD, Sigma) in serum-free medium at 37°C for 20
min. Cholesterol replenishment of cholesterol-depleted
cells was achieved by incubating cells with 1:10 (mol/
mol) complex of cholesterol and MβCD (cholesterol
water soluble, Sigma) using a 2.5 mM final cholesterol
concentration in serum-free medium at 37°C for 15 min.
Cholesterol levels in MβCD-treated cells were determined
using Amplex Red Cholesterol Assay kit (Molecular
Probes). Smase treatments were performed as previously
described [47].
Production of HCVpp and infection assays
HCVpp were produced as described previously [3,68]
with plasmids kindly provided by B. Bartosch and F.L.
Cosset (INSERM U412, Lyon, France). The plasmids
encoding HCV envelope glycoproteins of genotypes 1b
(UKN1B-5.23), 2b (UKN2B-1.1), 3a (UKN3A-1.28) and 4
(UKN4-11.1) were kindly provided by J. Ball (Notting-
ham University, UK) [69]. The genotype 1a plasmid
(strain H) has been described previously [3] and the gen-
otype 2a plasmid (strain JFH-1) was kindly provided by T.
Pietschmann and R. Bartenschlager (University of Heidel-
berg, Germany). Plasmids encoding the vesicular stomati-
tis virus glycoprotein G and feline endogenous virus
RD114 glycoprotein [70] were used for the production of
VSVpp and RD114pp, respectively. In each experiment,
pseudotyped particles produced in the absence of enve-
lope proteins were used as controls. The mean lumines-
cence activity of such particles represented less than 2% of
the activity measured for HCVpp. In cholesterol depletion
and Smase experiments, particles were produced in
DMEM containing 2% lipoprotein-depleted serum
(LPDS) [71]. At 40–48 h post-infection, cells were lysed
and processed to measure the Firefly luciferase activities as
indicated by the manufacturer (Promega). Luciferase
activities were normalized for protein concentration in
each cell lysate. In each figure, results are reported as the
mean ± S.D. of three independent experiments.
Detection of cell surface biotinylated proteins
Cells were biotinylated with 0.2 mg/mL EZ-link-Sulfo-
NHS-LC-biotin (Pierce) in Hanks buffered saline solution
(Invitrogen) for 30 minutes at 4°C. After 3 rinses with PBS
0.6% Bovine Serum Albumin (BSA, Euromedex), cells
were lysed in lysis buffer (1% Brij97 in D-PBS with Ca andPage 15 of 18
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taining protease inhibitors (Complete, Roche). Lysates
were precleared for 2 h at 4°C with protein A-sepharose
(Amersham Biosciences), then incubated for 2 h at 4°C
with specific mAbs immobilized onto protein A-sepha-
rose beads. After rinsing with the lysis buffer, complexes
were eluted with non-reducing Laemmli buffer, resolved
by SDS-PAGE and immunoblotted with peroxidase-con-
jugated Streptavidin (Vector).
Statistical analyses
The Mann-Whitney's test, based on ranks, was used to
compare the results to the reference. The reported p-values
were asymptotic and two-sided. We considered a differ-
ence as significant for any p-value < 0.05. The tests were
performed with the software SPSS 14.0.2.
Flow cytometry analysis
Cells were rinsed with PBS 2% Bovine Serum Albumin
(PBS/BSA) and incubated for 1 h at 4°C with anti-human
CD81 (1.3.3.22), anti-murine CD81 (MT81, MT81w) or
anti-human CD151 (TS151) mAbs. After rinsing with
PBS/BSA, cells were stained with phycoerythrin (PE)
labeled goat anti-mouse or anti-rat (BD Pharmingen) for
45 min at 4°C. After rinsing, cells were detached with PBS
2 mM EDTA and fixed with Formalin Solution (Sigma).
Cells stained only with the secondary antibodies were
used as negative control. Labelled cells were analyzed
using a FACS Beckman EPICS-XL MCL.
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